Related Experiment Video
Updated: Jun 3, 2026

A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease
Published on: January 29, 2021
Leptomeningeal disease in oligodendroglial tumors: a population-based study
Gloria Roldán1, Jennifer Chan, Misha Eliasziw
1Clark H. Smith Brain Tumor Center, Tom Baker Cancer Center, Alberta Health Services, HRIC 2AA07, 3330 Hospital Dr NW, Calgary, AB, T2N 4N1, Canada.
Abstract:
In this population-based study, we determined the frequency and clinical characteristics of leptomeningeal disease (LMD) developing in the context of oligodendroglial tumors (oligodendrogliomas and oligoastrocytomas). LMD occurred in only 3.9% (8/204) of oligodendroglial tumors and in patients with more recurrences [mean 2.88 vs. 1.27 in LMD and non-LMD, respectively (p = 0.001)]. In contrast to LMD from systemic solid tumors, the median survival following the diagnosis of LMD in oligodendroglial tumors was surprisingly long at 22 months (95% CI 11-33 months). Treatment with oral chemotherapy seemed as effective as more aggressive treatments (e.g. repeat RT or intrathecal chemotherapy) in these patients.

